Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Valneva SE is a specialty vaccine company focused on the development, manufacturing, and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The company operates within the biopharmaceuticals and vaccines industries, targeting both travel and endemic diseases as well as emerging public health threats. Its business model emphasizes late-stage clinical development and commercialization of differentiated vaccines rather than broad-based pharmaceutical portfolios.
Valneva was formed in 2013 through the merger of Vivalis SA and Intercell AG, combining cell-line technology, adjuvant expertise, and vaccine commercialization capabilities. Over time, the company has evolved from a predominantly R&D-focused organization into a commercial-stage vaccine manufacturer with approved products in international markets and a pipeline addressing diseases such as chikungunya, Lyme disease, and COVID‑19.
Business Operations
Valneva generates revenue primarily through its commercial vaccines segment and, to a lesser extent, through collaboration and licensing revenues tied to development partnerships. Key marketed vaccines include Ixiaro (Japanese encephalitis), Ixchiq (chikungunya), and historically Dukoral (cholera/traveler’s diarrhea). Public disclosures indicate some uncertainty regarding the current ownership and contribution of Dukoral to revenue due to divestment activity reported in recent years; data is inconclusive based on available public sources.
Operationally, Valneva maintains integrated capabilities across research, clinical development, manufacturing, and global distribution. The company operates manufacturing facilities in Europe and relies on a mix of direct sales and distribution partnerships to reach travelers, military customers, and public health agencies. Collaborative programs, including partnerships with larger pharmaceutical companies for co-development and commercialization, remain a core component of its operating strategy.
Strategic Position & Investments
Valneva’s strategic direction centers on becoming a leading provider of vaccines for niche and underserved infectious diseases. Growth initiatives include expanding commercialization of Ixchiq following regulatory approvals and advancing late-stage pipeline candidates such as a Lyme disease vaccine developed in partnership with Pfizer Inc. This collaboration represents one of Valneva’s most significant strategic investments and positions the company within a large potential endemic disease market.
The company has also invested heavily in inactivated whole-virus and recombinant vaccine platforms, which it views as a competitive advantage in safety and immunogenicity profiles. Valneva has periodically reshaped its portfolio through selective acquisitions and divestments to focus capital on higher-value assets; where disclosures differ on timing or financial impact, public data remains partially conflicting and is noted as such.
Geographic Footprint
Valneva SE is headquartered in Saint-Herblain, France, with major operational and research activities in Vienna, Austria. The company maintains a strong presence across Europe, with commercial reach extending into North America, Asia-Pacific, and selected emerging markets through distribution partners and government procurement channels.
Its vaccines are marketed internationally, particularly in regions with established travel medicine markets and in countries where endemic diseases such as Japanese encephalitis and chikungunya pose public health risks. Valneva’s global footprint is further supported by international clinical trial sites and regulatory engagements with authorities including European and U.S. regulators.
Leadership & Governance
Valneva is led by an executive team with extensive experience in vaccines, biotechnology, and global pharmaceutical commercialization. The leadership emphasizes disciplined capital allocation, partnership-driven development, and a focus on vaccines addressing clear unmet medical needs.
Key executives include:
- Thomas Lingelbach – Chief Executive Officer
- Franck Grimaud – Deputy Chief Executive Officer
- David Lawrence – Chief Financial Officer
- Juan Carlos Jaramillo – Chief Medical Officer
- Clément Debruyne – Chief Operating Officer
The company operates under a European governance framework with oversight by a supervisory board, reflecting its dual heritage and public listing structure.